SEC Comment Letter for Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196) (CANF) — Jul 22, 2025

Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196)
Date: July 22, 2025 · CIK: 0001536196 · Accession: 0000000000-25-007680

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-36203

Date

July 22, 2025

Author

Finance

Form

UPLOAD

Company

Can-Fite BioPharma Ltd. (CANF) (CIK 0001536196)

Letter

Re: Can-Fite BioPharma Ltd. Form 20-F for Fiscal Year Ended December 31, 2024 File No. 001-36203 Dear Motti Farbstein:

July 22, 2025

Motti Farbstein Chief Executive Officer and Chief Financial Officer Can-Fite BioPharma Ltd. 26 Ben Gurion St, Ramat Gan 5257346 Israel

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,
Division of Corporation
Finance
Office of Life Sciences

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 July 22, 2025

Motti Farbstein
Chief Executive Officer and Chief Financial Officer
Can-Fite BioPharma Ltd.
26 Ben Gurion St,
Ramat Gan 5257346 Israel

 Re: Can-Fite BioPharma Ltd.
 Form 20-F for Fiscal Year Ended December 31, 2024
 File No. 001-36203
Dear Motti Farbstein:

 We have completed our review of your filing. We remind you that the
company and
its management are responsible for the accuracy and adequacy of their
disclosures,
notwithstanding any review, comments, action or absence of action by the staff.

 Sincerely,

 Division of Corporation
Finance
 Office of Life Sciences
</TEXT>
</DOCUMENT>

SecProbe.io